A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high‐risk neuroblastoma

Neuroblastoma is a sympathetic nervous system tumor, primarily presenting in children under 6 years of age. The long‐term prognosis for patients with high‐risk neuroblastoma (HRNB) remains poor despite aggressive multimodal therapy. This report provides an update to a phase II trial evaluating DFMO...

詳細記述

保存先:
書誌詳細
出版年:Int J Cancer
主要な著者: Lewis, Elizabeth C., Kraveka, Jacqueline M., Ferguson, William, Eslin, Don, Brown, Valerie I., Bergendahl, Genevieve, Roberts, William, Wada, Randal K., Oesterheld, Javier, Mitchell, Deanna, Foley, Jessica, Zage, Peter, Rawwas, Jawhar, Rich, Maria, Lorenzi, Elizabeth, Broglio, Kristine, Berry, Donald, Saulnier Sholler, Giselle L.
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley & Sons, Inc. 2020
主題:
Cancer Therapy and Prevention
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7586843/
https://ncbi.nlm.nih.gov/pubmed/32391579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.33044
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料